Ebert, Thomas http://orcid.org/0000-0003-1683-9276
Painer, Johanna http://orcid.org/0000-0003-3929-511X
Bergman, Peter http://orcid.org/0000-0003-3306-3713
Qureshi, Abdul Rashid http://orcid.org/0000-0003-0536-5327
Giroud, Sylvain http://orcid.org/0000-0001-6621-7462
Stalder, Gabrielle
Kublickiene, Karolina
Göritz, Frank http://orcid.org/0000-0002-5353-7499
Vetter, Sebastian http://orcid.org/0000-0001-5374-5872
Bieber, Claudia http://orcid.org/0000-0001-8919-3117
Fröbert, Ole http://orcid.org/0000-0002-5846-345X
Arnemo, Jon M. http://orcid.org/0000-0001-8577-896X
Zedrosser, Andreas http://orcid.org/0000-0003-4417-3037
Redtenbacher, Irene
Shiels, Paul G.
Johnson, Richard J.
Stenvinkel, Peter http://orcid.org/0000-0002-8785-4820
Funding for this research was provided by:
Strategic Research Programme in Diabetes at Karolinska Institutet (2009-1068)
independent PhD Partnership awards between the University of Glasgow and Constant Pharma Ltd and 4D Pharma limited
Lundbeck Foundation (R126-2012-12408, R194-2015-1108, R286-2018-367)
Novo Nordisk postdoctoral fellowship
Njurfonden
European Foundation for the Study of Diabetes (EFSD Mentorship Programme supported by AstraZeneca)
Karolinska Institutet (Karolinska Institutet’s Research Foundation Grant 2020-2021)
Karolinska Institute
Article History
Received: 3 July 2020
Accepted: 27 October 2020
First Online: 23 November 2020
Competing interests
: The authors declare no competing interests.